Factor | Number (%) |
---|---|
Male sex | 26 (72.2) |
Age (years), mean ± SD | 9.5 ± 5.4 |
Underlying disorders | |
 Acute myeloid leukemia  Acute lymphoblastic leukemia  Severe aplastic anemia  Neuroblastoma  Lymphoma  Severe combined immune deficiency | 15 (41.7) 12 (33.3) 5 (13.9) 2 (5.6) 1 (2.8) 1 (2.8) |
Remission state of underlying malignancya | |
 Complete remission  Non-complete remission | 8 (26.7) 22 (73.3) |
Administered therapy preceding bacteremia | |
 Induction chemotherapy  Re-induction chemotherapy  Consolidation chemotherapy  Autologous hematopoietic cell transplantation  Allogeneic hematopoietic cell transplantation  Palliative chemotherapy  Noneb | 2 (5.6) 13 (36.1) 6 (16.7) 1 (2.8) 4 (11.1) 7 (19.4) 3 (8.3) |
Central venous catheter | |
 Hickman catheter  Subcutaneously implanted chemoport  None | 27 (75.0) 7 (19.4) 2 (5.6) |
Polymicrobial infection | 9 (25.0) |
Breakthrough infection | 8 (22.2) |
Local infection  Gastrointestinal tract infection  Respiratory tract infection  Skin and soft tissue infection  Catheter site infection | 26 (72.2) 15 (41.7) 11 (30.6) 7 (19.4) 2 (5.6) |
Empirical antibiotic therapy | |
 Piperacillin/tazobactam with aminoglycoside  Meropenem  Cefepime  Cefepime with aminoglycoside  Meropenem with aminoglycoside | 16 (44.4) 14 (38.9) 3 (8.3) 2 (5.6) 1 (2.8) |
Empirical combination antibiotic therapy | 19 (52.8) |
Appropriateness of empirical antibiotics | |
 Overall  β-lactam agents | 30 (83.3) 24 (66.7) |
Fever duration (days), median (range) | 4 (1–53) |
Complications  Hypoxia  Shock  Mechanical ventilator care  Renal dysfunction  Hepatic dysfunction | 17 (47.2) 14 (38.9) 13 (36.1) 8 (22.2) 8 (22.2) 4 (11.1) |
Death | 14 (38.9) |
Multidrug-resistant strain infections | 13 (36.1) |